GYRE Gyre Therapeutics Inc

Price (delayed)

$7.4

Market cap

$825.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.2

Enterprise value

$785.3M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 65
Relative Valuation: Rel. Valuation: 11
Relative Profitability: Rel. Profitability: 28

Catalyst Biosciences, Inc. and its subsidiary (the “Company” or “Catalyst”) is a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, the ...

Highlights
The company's equity rose by 17% YoY and by 7% QoQ
GYRE's revenue is up by 14% year-on-year
The net income has plunged by 181% from the previous quarter
Gyre Therapeutics's debt has surged by 145% YoY

Key stats

What are the main financial stats of GYRE

GYRE stock price

How has the Gyre Therapeutics stock price performed over time
Intraday
-1.2%
1 week
10.45%
1 month
7.09%
1 year
1.37%
YTD
4.82%
QTD
12.29%

Financial performance

How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$119.38M
Gross profit
$112.58M
Operating income
-$16.68M
Net income
-$17.41M
Gross margin
94.3%
Net margin
-14.6%
The net income has plunged by 181% from the previous quarter
Gyre Therapeutics's net margin has shrunk by 181% QoQ
GYRE's revenue is up by 14% year-on-year
GYRE's gross profit is up by 11% year-on-year

Price vs fundamentals

How does GYRE's price correlate with its fundamentals

Growth

What is Gyre Therapeutics's growth rate over time

Valuation

What is Gyre Therapeutics stock price valuation
P/E
N/A
P/B
6.65
P/S
6.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.58
GYRE's EPS has dropped by 100% since the previous quarter
GYRE's P/B is 18% below its 5-year quarterly average of 8.2 and 11% below its last 4 quarters average of 7.6
The company's equity rose by 17% YoY and by 7% QoQ
GYRE's revenue is up by 14% year-on-year
The stock's price to sales (P/S) is 13% more than its last 4 quarters average of 5.6 but 12% less than its 5-year quarterly average of 7.2

Efficiency

How efficient is Gyre Therapeutics business performance
The ROE has dropped by 100% since the previous quarter
Gyre Therapeutics's ROA has plunged by 96% from the previous quarter

Dividends

What is GYRE's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Gyre Therapeutics financials performed over time
The company's total liabilities rose by 48% YoY and by 37% QoQ
GYRE's total assets is up by 31% year-on-year and by 23% since the previous quarter
Gyre Therapeutics's debt is 97% lower than its equity
Gyre Therapeutics's debt to equity has surged by 200% QoQ and by 50% YoY
Gyre Therapeutics's debt has surged by 145% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.